Search Results for “Roche” – Page 6 – media

Robust start to 2018 for Roche, as group sales grow by 6%

In the first quarter of 2018, Swiss pharmaceuticals and diagnostics player Roche group’s sales rose by 6% to CHF 13.6 billion. Sales in the pharma division increased by 7% CHF 10.7 billion mainly by strong growth in Ocrevus and Perjeta.
- Source: drugdu
- 820
- May 4, 2018
Company Insights Roche
ROCHE TO BUY FLATIRON HEALTH FOR $1.9 BN TO EXPAND CANCER CARE

Swiss drugmaker Roche Holding AG (ROG.S) said on Thursday it would buy the rest of U.S. cancer data company Flatiron Health for $1.9 billion (1.35 billion pounds) to speed development of cancer medicines and support its efforts to price them based on how well they work.
- Source: Reuters
- 501
- March 15, 2018
cancer Market Views
Cipla Partners With Roche Pharma India To Create Greater Access To Key Medicines

Cipla Ltd. and Roche Products (India) Private Limited have signed a distribution agreement for the promotion and sale of tocilizumab and the 2nd brand of bevacizumab.
- Source: Cipla
- 694
- March 1, 2018
Cipla Company Insight India Roche
Breakthrough status for Roche’s autism drug

Roche’s balovaptan has picked up a Breakthrough Therapy Designation in the US for its potential as a treatment for people with autism spectrum disorder (ASD), potentially placing the drug on a faster path to market.
- Source: pharmatimes
- 621
- February 5, 2018
ASD balovaptan New Approvals Roche
FDA Calls Roche’s Autism Drug a Breakthrough

An experimental Roche drug designed to improve social interaction in people with autism scored the U.S. Food and Drug Administration’s Breakthrough Therapy Designation.
- Source: Biospace
- 720
- January 31, 2018
autism New Approvals
GE Healthcare and Roche join forces to create clinical decision support tools

GE Healthcare and Roche have launched a partnership to assist clinicians in making better choices and help patients get individualized care.
- Source: MedCityNews
- 576
- January 12, 2018
Clinical Company Insight Roche
Roche introduces new sample collection device for HIV plasma viral load testing

The new card solution helps to simplify blood collection and sample transportation through providing a small amount of a patient’s blood from a fingertip.
- Source: MDBR
- 506
- January 9, 2018
Company Insight HIV Roche
Roche snags another Perjeta combo nod, but will ‘weak’ data limit its use?

Analysts and investors think Perjeta’s end-of-the-year indication may not be as lucrative as they once hoped. The FDA green-lighted the drug in tandem with giant Herceptin and chemo for HER2-positive, post-surgery breast cancer patients with a high risk of recurrence. Patients should receive up to 18 cycles of the regimen over the course of one year, according to the indication.
- Source: fiercepharma
- 558
- December 28, 2017
breast cancer Company Insight FDA HER2-positive
Roche and Ignyta Reach Definitive Merger Agreement

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. (NASDAQ: RXDX) today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta at a price of US$ 27.00 per share in an all-cash transaction. This corresponds to a total transaction value of US$ 1.7 billion on a fully diluted basis. This price represents a premium of 74% to Ignyta’s closing price on 21 December 2017 and a premium of 71% and 89% to Ignyta’s 30-day and 90-day volume weighted average share price on 21 December 2017, respectively. The merger agreement has been unanimously approved by the boards of Ignyta and Roche.
- Source: Roche
- 528
- December 25, 2017
Ignyta Market Views Roche
EU OKs first-line use of Roche’s lung cancer drug Alecensa

Roche’s Alecesna has been cleared for use in Europe as a first-line treatment for ALK-positive non-small cell lung cancer (NSCLC), offering a new option for patients newly diagnosed with the disease.
- Source: Pharmatimes
- 473
- December 22, 2017
Alecesna New Approvals NSCLC

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.